New Oral Weight Loss Pill Launches in Israel, Offering Injection-Free Alternative

Israel is set to become the fourth country globally to launch a new oral weight loss medication, "Pill-form Tirzepatide" (brand name: "Poundaio"), on September 15. Developed by Eli Lilly, this drug represents the first oral treatment in the GLP-1 class, providing an alternative to injectable medications for obesity management. This launch positions Eli Lilly ahead of competitor Novo Nordisk in the Israeli market.

The medication will be available by prescription only for adults struggling with obesity or overweight conditions accompanied by other health issues. The monthly cost will range from approximately 691 to 1,146 shekels, depending on the dosage. Health authorities are also considering its inclusion in the national health basket.

A key advantage of Poundaio is its ease of use. Unlike weekly injections or other oral medications that require specific timing around meals, Poundaio can be taken at any time without dietary restrictions or the need for refrigeration. Clinical studies demonstrated an average weight loss of about 12.4%, along with improvements in cholesterol, blood pressure, and blood sugar levels.

While the weight loss percentage is slightly lower than that of injectable treatments, the pill is seen as an ideal option for individuals who are averse to needles or prefer a more convenient long-term weight management solution. Experts caution, however, that oral administration does not eliminate common GLP-1 side effects, primarily gastrointestinal issues like nausea and diarrhea, which can lead to treatment discontinuation for around 10% of users.

As the weight loss market expands with various options, including biological drugs and mechanical aids like intragastric balloons, initiating treatment with Poundaio necessitates close medical supervision, gradual dosage increases, and a comprehensive approach combining dietary changes and physical activity.